Ollin Biosciences
A clinical-stage biotech advancing therapies for vision-threatening diseases.
A clinical-stage biotech advancing therapies for vision-threatening diseases. Headquartered in Austin, TX. Raised $330M in Series B funding in June 2026 led by TCGX.
Healthcare
📍 Austin, TX
Founded 2023
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Ollin Biosciences going public?
No. Ollin Biosciences is private and has not filed to go public. There is no S-1 on file.
What is Ollin Biosciences' valuation in 2026?
No confirmed valuation is on record for Ollin Biosciences. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Ollin Biosciences filed an S-1?
No public S-1 is on file for Ollin Biosciences.
Who are Ollin Biosciences' investors?
Ollin Biosciences' investors include TCGX, ARCH Venture Partners, a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, CPP Investments and 4 more.
How much has Ollin Biosciences raised?
Ollin Biosciences has raised $330M in total across 1 disclosed round, most recently a Series B of $330M in Jun 2026.
Is Ollin Biosciences publicly traded — can you buy Ollin Biosciences stock?
No. Ollin Biosciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Ollin Biosciences on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Last Round
Series B — $330M (Jun 2026) · Lead: TCGX
Fundraising Status
Series B · $330M · 3 mo ago
privateTotal raised $330M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series B | $330M | Jun 2026 | TCGX | — |
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
3
2 active · 0 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Wet Age Related Macular Degeneration
Wet Age-related Macular Degeneration · Diabetic Macular Edema (DME)
Latest trial start
2026-10-15
Talent Signal
No public careers page or job board could be found for Ollin Biosciences as of 2026-09-14. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Investors
TCGX · ARCH Venture Partners · a16z Bio+Health · Blackstone Multi-Asset Investing · Commodore Capital · CPP Investments · RA Capital Management · T. Rowe Price Investment Management · Mubadala Capital · Monograph Capital
HealthcareBiotechnologyRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.